Inducible arginase 1 deficiency in mice leads to hyperargininemia and altered amino acid metabolism

PLoS One. 2013 Nov 4;8(11):e80001. doi: 10.1371/journal.pone.0080001. eCollection 2013.

Abstract

Arginase deficiency is a rare autosomal recessive disorder resulting from a loss of the liver arginase isoform, arginase 1 (ARG1), which is the final step in the urea cycle for detoxifying ammonia. ARG1 deficiency leads to hyperargininemia, characterized by progressive neurological impairment, persistent growth retardation and infrequent episodes of hyperammonemia. Using the Cre/loxP-directed conditional gene knockout system, we generated an inducible Arg1-deficient mouse model by crossing "floxed" Arg1 mice with CreER(T2) mice. The resulting mice (Arg-Cre) die about two weeks after tamoxifen administration regardless of the starting age of inducing the knockout. These treated mice were nearly devoid of Arg1 mRNA, protein and liver arginase activity, and exhibited symptoms of hyperammonemia. Plasma amino acid analysis revealed pronounced hyperargininemia and significant alterations in amino acid and guanidino compound metabolism, including increased citrulline and guanidinoacetic acid. Despite no alteration in ornithine levels, concentrations of other amino acids such as proline and the branched-chain amino acids were reduced. In summary, we have generated and characterized an inducible Arg1-deficient mouse model exhibiting several pathologic manifestations of hyperargininemia. This model should prove useful for exploring potential treatment options of ARG1 deficiency.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acids / metabolism*
  • Amino Acids, Branched-Chain / metabolism
  • Animals
  • Arginase / genetics
  • Arginase / metabolism*
  • Female
  • Hyperargininemia / enzymology*
  • Hyperargininemia / genetics
  • Hyperargininemia / metabolism*
  • Male
  • Mice
  • Mice, Knockout

Substances

  • Amino Acids
  • Amino Acids, Branched-Chain
  • Arg1 protein, mouse
  • Arginase

Grants and funding

CDF holds a Tier I Canada Research Chair in Molecular, Cellular, and Physiological Medicine and is recipient of a Career Investigator Award from the Heart and Stroke Foundation of Ontario. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.